Overview

This trial is active, not recruiting.

Condition small cell lung cancer
Treatments cisplatin, etoposide, placebo, zd6474
Phase phase 2
Targets VEGF, EGFR
Sponsor Hoosier Cancer Research Network
Collaborator AstraZeneca
Start date January 2008
End date May 2013
Trial size 74 participants
Trial identifier NCT00613626, LUN06-113

Summary

At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver)
Primary purpose treatment
Arm
(Placebo Comparator)
Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
cisplatin
Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
etoposide
Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
placebo
Matched placebo oral daily
(Active Comparator)
Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
cisplatin
Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
etoposide
Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
zd6474
ZD6474 100mg oral daily to be continued for the duration of the study.

Primary Outcomes

Measure
The primary objective will be to evaluate whether the addition of ZD6474 to EP improves time to disease progression over EP alone.
time frame: 24 months

Secondary Outcomes

Measure
Evaluate the safety and tolerability of this treatment combination
time frame: 6 months
Measure the response rate (CR + PR) in each arm
time frame: 24 months
Measure disease control rate (CR + PR+ SD) in each arm
time frame: 24 months
Measure overall survival for each arm
time frame: 24 months
Assess VEGF Polymorphisms and correlate subject response
time frame: 24 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histological or cytological proof of chemotherapy-naïve, extensive, small cell lung cancer. - Measurable disease according to RECIST and obtained by imaging within 28 days prior to being registered for protocol therapy. - Written informed consent and HIPAA authorization for release of personal health information. - Age 18 years or older at the time of consent. - Potassium ≥4.0 mmol/L and <5.5mmol/L (supplementation is allowed). - Calcium within normal range (supplementation is allowed). - Magnesium within normal range (supplementation is allowed). Exclusion Criteria: - No prior EGFR inhibitor or antiangiogenic agent allowed. - No prior hormonal therapy. - No symptomatic brain metastasis. - No clinically significant infections as judged by the treating investigator. - No evidence of severe or uncontrolled other systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol. - No previous history of QTc prolongation as a result of medication that required discontinuation of that medication. - No congenital long QT syndrome or known 1st degree relative with unexplained sudden death under 40 years of age. - No presence of left bundle branch block (LBBB.) - No QTc with Bazett's correction that is unmeasurable, or ≥480 msec on screening ECG obtained within 7 days prior to registration for protocol therapy. If a subject has QTc ≥480 msec on screening ECG, the screen ECG may be repeated twice (at least 24 hours apart). The average QTc from the three screening ECGs must be <480 msec in order for the subject to be eligible for the study. - No concomitant (within 14 days prior to registration for and during protocol therapy) medication associated with Torsades de Pointes or cause QTc prolongation, is allowed. Medications that prolong QT, but are not strictly associated with Torsades, are allowed if medically necessary and will require increased ECG and electrolyte monitoring. - No uncontrolled hypertension (systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg). - No currently active diarrhea that may affect the ability to absorb ZD6474. - No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason < grade 7 prostate cancers, or other cancer for which the subject has been disease-free for at least 5 years. - Major surgery must be completed greater than 28 days prior to registration for protocol therapy and healed surgical incision is required. - No concomitant (within 14 days prior to registration for and during protocol therapy) medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of CYP3A4 function. - Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation. - Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. - Females must not be breastfeeding.

Additional Information

Official title A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Description OUTLINE: This is a multi-center study. Arm A: Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + Placebo oral daily given continuously for the duration of the study Arm B: Cisplatin 60mg/m2 Day 1 + Etoposide 120mg/m2 Day 1,2,3 + ZD6474 100mg oral daily given continuously for the duration of the study For both arms, PE and toxicity evaluation prior to each cycle and disease assessment by imaging every 2 cycles. Patients with non-PD and acceptable toxicity will continue protocol therapy; patients with progressive disease or excessive toxicity will be taken off treatment. Cycles will be repeated every 21 days up to a total of 4 cycles. ECOG Performance Status of 0 or 1 Life Expectancy: Not specified Hematopoietic: - Platelets > 100K/mm3 - Absolute neutrophil count (ANC) > 1.5K/mm3 Hepatic: - Bilirubin < 1.5 x ULN - Aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if judged by the investigator to be related to liver metastases - Alkaline phosphatase < 2.5 x ULN or < 5 x ULN if judged by the investigator to be related to liver metastases Renal: - Serum creatinine < 1.5 x ULN or Calculated creatinine clearance of > 45 cc/min using the Cockcroft-Gault formula Cardiovascular: - No clinically significant cardiac event such as myocardial infarction; New York Heart Association (NYHA) classification of heart disease >2 (see SPM) within 3 months prior to registration for protocol therapy - No presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia. - No history of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is permitted.
Trial information was received from ClinicalTrials.gov and was last updated in August 2014.
Information provided to ClinicalTrials.gov by Hoosier Cancer Research Network.